Lipid Metabolism Modulation by a Flavonoid-Standardized Citrus Bergamia Extract in an Asian Population: Findings From a Double-Blind, Placebo-Controlled Clinical Trial

Genetic factors, dietary habits, and lifestyle may influence individual responses to supplementation, including the bergamot flavanones naringin and naringenin, which are implicated in lipid modulation. The aim of this double-blind, placebo-controlled clinical trial (RCT) is to assess the effects of the supplementation for four months of a standardised bergamot extract at the dosage of 375 mg/day, providing 150 mg/day of flavonoids, on lipid parameters of 108 East Asian adults with LDL-Cholesterol (LDL-C) 100-159 mg/day, since to date, the RCTs have been conducted on Caucasian subjects only. After 4 months, total Cholesterol and LDL-C decreased (-7.3% and -7.0%) with no clinically relevant safety changes regarding hepatic/renal biochemistry, weight, and blood pressure.